Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 95 of 165 for:    personality AND therapy AND severity | Recruiting, Not yet recruiting, Available Studies

Cognitive Behavioural Therapy for the Treatment of Late Life Depression (CBTlate)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03735576
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : December 7, 2018
Sponsor:
Information provided by (Responsible Party):
Frank Jessen, University of Cologne

Brief Summary:
This study addresses the unmet medical problem of insufficient treatment of late life depression (LLD). Compared with depression in early adulthood, treatment options of LLD are limited. This trial is the first confirmatory multicentre study to test the efficacy of an LLD-adapted cognitive behavioural therapy (CBT) program. It will test the hypothesis, that LLD-specific cognitive behavioural therapy (CBT) is superior to unspecific supportive intervention (SUI) with regard to reducing symptoms of depression over the course of 6 months. Secondary goals are to test the efficacy of LLD-CBT in comparison with SUI on patient reported outcome in major depressive disorders (PRO-MDD), anxiety, cognition, quality of life, overall health status, sleep and global clinical impression.

Condition or disease Intervention/treatment Phase
Late-life Depression Major Depressive Disorder Major Depressive Episode Major Depressive Disorder, Recurrent Behavioral: Psychotherapy Diagnostic Test: Questionnaires Other: Magnetic Resonance Imaging Other: Blood analysis Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 248 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, multi-center, single blind (observer-blinded), active-controlled, parallel group trial (therapeutic confirmatory) in 248 patients with late-life depression of both genders at 7 trial sites in Germany. The intervention includes 8 weeks of manual-based, individual, 15-session, twice weekly, outpatient treatment for patients with late life depression in each arm of the trial.
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cognitive Behavioural Therapy for the Treatment of Late Life Depression - a Multicentre, Randomized, Observer- Blinded, Controlled Trial (CBTlate)
Actual Study Start Date : October 1, 2017
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LLD-adapted cognitive behavioural therapy (CBT)
manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
Behavioral: Psychotherapy
15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity

Diagnostic Test: Questionnaires
There will be a total of four assessments (see primary & secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.

Other: Magnetic Resonance Imaging
Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.

Other: Blood analysis
Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.

Active Comparator: supportive unspecific intervention (SUI)
manualized 15-session individually-delivered supportive unspecific intervention (SUI)
Behavioral: Psychotherapy
15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity

Diagnostic Test: Questionnaires
There will be a total of four assessments (see primary & secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.

Other: Magnetic Resonance Imaging
Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.

Other: Blood analysis
Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.




Primary Outcome Measures :
  1. Change of Geriatric Depression Scale (GDS) Score [ Time Frame: 10 weeks ]
    The primary end point is the change in depression severity from baseline to week 10 measured by the 30-item Geriatric Depression Scale (GDS). It is a self-rating scale including 30 Items in a yes/no format and a total score range from 0 to 30. Higher values represent worse outcome.


Secondary Outcome Measures :
  1. Change of Geriatric Depression Scale (GDS) Score [ Time Frame: 5 weeks ]
    A secondary outcome measure is the change in depression severity from baseline to week 5 measured by the 30-item Geriatric Depression Scale (GDS). It is a self-rating scale including 30 Items in a yes/no format and a total score range from 0 to 30. Higher values represent worse outcome.

  2. Change of Geriatric Depression Scale (GDS) Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in depression severity from baseline to month 6 measured by the 30-item Geriatric Depression Scale (GDS). It is a self-rating scale including 30 Items in a yes/no format and a total score range from 0 to 30. Higher values represent worse outcome.

  3. Change of Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C) [ Time Frame: 5 weeks ]
    A secondary outcome measure is the change in depression severity from baseline to week 5 measured by the 16-item Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C). It is a clinician-rated scale including 16 Items and a total score range from 0 to 27. Higher values represent worse outcome.

  4. Change of Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C) [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in depression severity from baseline to week 10 measured by the 16-item Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C). It is a clinician-rated scale including 16 Items and a total score range from 0 to 27. Higher values represent worse outcome.

  5. Change of Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C) [ Time Frame: 6 months ]
    A secondary outcome measure is the change in depression severity from baseline to month 6 measured by the 16-item Quick Inventory of Depressive Symptomatology Score - Clinician Rating (QIDS-C). It is a clinician-rated scale including 16 Items and a total score range from 0 to 27. Higher values represent worse outcome.

  6. Change of Patient Reported Outcome for Major Depressive Disorder (PRO-MDD) Score [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in depression severity from baseline to week 10 measured by the 35-item Patient Reported Outcome for Major Depressive Disorder (PRO-MDD) Score. It is a self-rating scale including 35 Items on an11-point numeric rating scale. Higher values represent worse outcome.

  7. Change of Patient Reported Outcome for Major Depressive Disorder (PRO-MDD) Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in depression severity from baseline to month 6 measured by the 35-item Patient Reported Outcome for Major Depressive Disorder (PRO-MDD) Score. It is a self-rating scale including 35 Items on an11-point numeric rating scale. Higher values represent worse outcome.

  8. Longitudinal Interval Follow-up Evaluation (LIFE) [ Time Frame: 6 months ]
    A secondary outcome measure is the longitudinal evaluation of depressive symptoms by the Longitudinal Interval Follow-up Evaluation Interview (LIFE) at month 6.

  9. Change of Insomnia Severity Index (ISI) Score [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in insomnia severity from baseline to week 10 measured by the 7-item Insomnia Severity Index (ISI). It is a self-rating scale including 7 Items rated on a scale from 0 to 4 from less to more severe. The total score ranges from 0 to 28. Higher values represent worse outcome.

  10. Change of Insomnia Severity Index (ISI) Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in insomnia severity from baseline to month 6 measured by the 7-item Insomnia Severity Index (ISI). It is a self-rating scale including 7 Items rated on a scale from 0 to 4 from less to more severe. The total score ranges from 0 to 28. Higher values represent worse outcome.

  11. Change of Epworth Sleepiness Scale (ESS) Score [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in sleepiness from baseline to week 10 measured by the 8-item Epworth Sleepiness Scale (ESS). It is a self-rating scale including 8 Items rated on a 4-point Likert scale. The total score ranges from 0 to 24. Higher values represent worse outcome.

  12. Change of Epworth Sleepiness Scale (ESS) Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in sleepiness from baseline to month 6 measured by the 8-item Epworth Sleepiness Scale (ESS). It is a self-rating scale including 8 Items rated on a 4-point Likert scale. The total score ranges from 0 to 24. Higher values represent worse outcome.

  13. Change of REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)Score [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in REM sleep behavior from baseline to week 10 measured by the 10-item REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ). It is a self-rating scale including 10 Items in a yes/no format. The total score ranges from 0 to 13. Higher values represent worse outcome.

  14. Change of REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ)Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in REM sleep behavior from baseline to month 6 measured by the 10-item REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ). It is a self-rating scale including 10 Items in a yes/no format. The total score ranges from 0 to 13. Higher values represent worse outcome.

  15. Change of Geriatric Anxiety Inventory (GAI) Score [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in anxiety symptoms from baseline to week 10 measured by the 20-item Geriatric Anxiety Inventory (GAI). It is a self-rating scale including 20 Items in a agree/disagree format and a total score range from 0 to 20. The cut-off score of 9 classifies the presence of clinically significant anxiety. Higher values represent worse outcome.

  16. Change of Geriatric Anxiety Inventory (GAI) Score [ Time Frame: 6 months ]
    A secondary outcome measure is the change in anxiety symptoms from baseline to month 6 measured by the 20-item Geriatric Anxiety Inventory (GAI). It is a self-rating scale including 20 Items in a agree/disagree format and a total score range from 0 to 20. The cut-off score of 9 classifies the presence of clinically significant anxiety. Higher values represent worse outcome.

  17. Change in Quality of Life (WHOQOL) [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in quality of life from baseline to week 10 measured by the 24-item WHOQOL-OLD and 26-item WHOQOL-BREF.

  18. Change in Quality of Life (WHOQOL) [ Time Frame: 6 months ]
    A secondary outcome measure is the change in quality of life from baseline to month 6 measured by the 24-item WHOQOL-OLD and 26-item WHOQOL-BREF.

  19. Change in Short Form Health Survey (SF-36) [ Time Frame: 10 weeks ]
    A secondary outcome measure is the change in overall health status from baseline to week 10 measured by the 36-item Short Form Health Survey (SF-36).

  20. Change in Short Form Health Survey (SF-36) [ Time Frame: 6 months ]
    A secondary outcome measure is the change in overall health status from baseline to month 6 measured by the 36-item Short Form Health Survey (SF-36).

  21. Change in Subjective Cognitive Functioning [ Time Frame: 6 months ]
    A secondary outcome measure is the change in subjective cognitive functioning from baseline to month 6 measured by the semi-structured Subjective Cognitive Decline interview.

  22. Change in cognitive function (CERAD-Plus) [ Time Frame: 6 months ]
    A secondary outcome measure is the change in cognitive function from baseline to month 6 measured by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-Plus) neuropsychological test battery.

  23. Change in executive function (NAB maze test) [ Time Frame: 6 months ]
    A secondary outcome measure is the change in executive function from baseline to month 6 measured by the Neuropsychological Assessment Battery (NAB) maze subtest.

  24. Childhood Trauma Questionnaire (CTQ) [ Time Frame: baseline ]
    Assessment of the severity of five categories of childhood trauma(emotional/physical/sexual abuse and emotional/physical neglect) at baseline

  25. Big Five-Inventory 10 Item Short Version (BFI-10) [ Time Frame: baseline ]
    10-item scale measuring the personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness to assess the influence of personality traits on treatment outcome at baseline. The items are rated on a five-step scale from 1 "disagree strongly" to 5 "agree strongly". The scale consists of 2 BFI items for each Big Five Dimension.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • out-patient status
  • male or female, age ≥ 60 years
  • ability to provide informed consent and written informed consent signed
  • DSM-5 diagnosis of a Major Depressive Disorder/MDD (depressive episode at least moderate to severe)
  • score of at least 10 on the Geriatric Depression Scale (GDS)
  • score of at least 10 on the Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)
  • score of at least 25 in the Mini-Mental-Status-Test (MMST)
  • no or stable (≥ 6 weeks) antidepressive pharmacological treatment at baseline (medication will be kept stable at least throughout the 8 weeks of treatment).
  • sufficient German language skills

Exclusion Criteria:

  • Bipolar depression
  • Schizophrenia or other psychotic disorders
  • Substance abuse or dependency
  • Dementia
  • Acute suicidality
  • Anxiety disorder as stand-alone diagnosis (e.g. generalized anxiety disorder, panic disorder, social phobia)
  • Obsessive-compulsive disorder (OCD) as stand-alone diagnosis
  • Participation in any another clinical trial parallel to this trial
  • Additional psychological/psychotherapeutic treatment throughout the 8-week treatment period
  • Regular use with scheduled daily dosing of benzodiazepines (not PRN) during 8-week treatment
  • Severe or instable medical condition, which clearly impacts on depression or on the ability to participate in the trial
  • Brain disease with severe functional impairement that impacts the ability to participate in the trial (e.g. aphasia, Parkinson's disease)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03735576


Contacts
Layout table for location contacts
Contact: Forugh S. Dafsari, Dr.med. +49-(0)221-478-62035 forugh.salimi-dafsari@uk-koeln.de

Locations
Layout table for location information
Germany
Charité Berlin Recruiting
Berlin, Germany
Contact: Oliver Peters         
University of Bonn Recruiting
Bonn, Germany
Contact: Michael Wagner         
University of Cologne Recruiting
Cologne, Germany
Contact: Forugh S. Dafsari         
University of Freiburg Recruiting
Freiburg, Germany
Contact: Elisabeth Schramm         
University of Leipzig Recruiting
Leipzig, Germany
Contact: Melanie Luppa         
ZI Mannheim Recruiting
Mannheim, Germany
Contact: Lutz Frölich         
University of Tuebingen Recruiting
Tuebingen, Germany
Contact: Martin Hautzinger         
Sponsors and Collaborators
University of Cologne
Investigators
Layout table for investigator information
Principal Investigator: Frank Jessen, Prof.Dr. University of Cologne

Layout table for additonal information
Responsible Party: Frank Jessen, Prof. Dr., University of Cologne
ClinicalTrials.gov Identifier: NCT03735576     History of Changes
Other Study ID Numbers: 01KG1716
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Frank Jessen, University of Cologne:
Late-life depression
Psychotherapy
Major depression
Randomized controlled trial
Treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Depression
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Mental Disorders